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AIM: To investigate the activity and expression of EAAT2 glutamate transporter
in both in vitro and in vivo models of cholestasis. METHODS: This study was
conducted on human hepatoblastoma HepG2 cell cultures, the liver of bile duct
ligated rats and human specimens from cholestatic patients. EAAT2 glutamate
transporter activity and expression were analyzed using a substrate uptake
assay, immunofluorescence, reverse transcription-polymerase chain reaction,
and immunohistochemistry, respectively. RESULTS: In HepG2 cells, cholestasis
was mimicked by treating cells with the protein kinase C activator, phorbol 12-
myristate 13-acetate. Under such conditions, EAAT2 transporter activity was
decreased both at the level of substrate affinity and maximal transport velocity.
The decreased uptake was correlated with intracellular translocation of EAAT2
molecules as demonstrated using immunofluorescence. In the liver of bile duct
ligated rats, an increase in EAAT2 transporter protein expression in...
Document type : Article de périodique (Journal article)
Référence bibliographique
Najimi, Mustapha ; Stéphenne, Xavier ; Sempoux, Christine ; Sokal, Etienne. Regulation of
hepatic EAAT-2 glutamate transporter expression in human liver cholestasis. In: World Journal of
Gastroenterology, Vol. 20, no. 6, p. 1554 (2014)
DOI : 10.3748/wjg.v20.i6.1554
ORIGINAL ARTICLE
Regulation of hepatic EAAT-2 glutamate transporter 
expression in human liver cholestasis
Mustapha Najimi, Xavier Stéphenne, Christine Sempoux, Etienne Sokal
Mustapha Najimi, Xavier Stéphenne, Etienne Sokal, Uni-
versité Catholique de Louvain, Institut de Recherche Expéri-
mentale et Clinique (IREC), Laboratory of Pediatric Hepatology 
and Cell Therapy, Brussels 1200, Belgium
Christine Sempoux, Anatomo-pathology, Cliniques Universi-
taires St-Luc, Université Catholique de Louvain, Brussels 1200, 
Belgium
Author contributions: Najimi M performed the majority 
of experiments; Najimi M designed the study and wrote the 
manuscript; Stéphenne X participated in performing the in vivo 
experiments on rats; Stéphenne X, Sempoux C and Sokal E 
were involved in revising the manuscript; Sempoux C provided 
the human liver samples, supervised the immunohistochemistry 
analyses; Sokal E provided the financial support.
Correspondence to: Mustapha Najimi, PhD, Université 
Catholique de Louvain, Institut de Recherche Expérimentale et 
Clinique (IREC), Laboratory of Pediatric Hepatology and Cell 
Therapy, Avenue Mounier 52, Brussels 1200, 
Belgium. mustapha.najimi@uclouvain.be
Telephone: +32-2-7645283  Fax: +32-2-7645258
Received: April 23, 2013      Revised: September 9, 2013
Accepted: September 16, 2013
Published online: February 14, 2014 
Abstract
AIM: To investigate the activity and expression of 
EAAT2 glutamate transporter in both in vitro  and in 
vivo  models of cholestasis.
METHODS: This study was conducted on human hep-
atoblastoma HepG2 cell cultures, the liver of bile duct 
ligated rats and human specimens from cholestatic 
patients. EAAT2 glutamate transporter activity and ex-
pression were analyzed using a substrate uptake assay, 
immunofluorescence, reverse transcription-polymerase 
chain reaction, and immunohistochemistry, respectively. 
RESULTS: In HepG2 cells, cholestasis was mimicked by 
treating cells with the protein kinase C activator, phor-
bol 12-myristate 13-acetate. Under such conditions, 
EAAT2 transporter activity was decreased both at the 
level of substrate affinity and maximal transport veloc-
ity. The decreased uptake was correlated with intracel-
lular translocation of EAAT2 molecules as demonstrated 
using immunofluorescence. In the liver of bile duct 
ligated rats, an increase in EAAT2 transporter protein 
expression in hepatocytes was demonstrated using im-
munohistochemistry. The same findings were observed 
in human liver specimens of cholestasis in which high 
levels of γ-glutamyl transpeptidase were documented 
in patients with biliary atresia and progressive familial 
intrahepatic cholestasis type 3.
CONCLUSION: This study demonstrates the alteration 
in glutamate handling by hepatocytes in liver cholesta-
sis and suggests a potential cross-talk between gluta-
matergic and bile systems.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The aim of the current study was to demon-
strate the role of glutamate transport, the most abun-
dant intracellular hepatic amino acid, in liver cholesta-
sis. The study was conducted in vitro  using HepG2 cells 
as well as the livers of bile duct ligated rats and human 
cholestasis specimens. The principal data revealed that 
the activity and expression of EAAT2-mediated gluta-
mate transport were altered both in vitro  and in vivo . 
This supports the involvement of glutamate transport-
ers, as an indirect liver response and/or as a direct 
hepatic target, in restoring intracellular pools of this 
amino acid which are probably altered after cholestasis. 
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INTRODUCTION
The liver is considered to be the major site of  amino 
acid and protein homeostasis. Of  these amino acids, 
L-glutamate is the most abundant intracellular amino 
acid. Accordingly, this intermediate is involved in a wide 
variety of  liver metabolic pathways such as ureagenesis, 
gluconeogenesis and glutathione synthesis. The intracel-
lular availability of  glutamate is highly controlled both 
at the level of  synthesis, after conversion of  a variety 
of  precursors, and uptake from the extracellular en-
vironment. High glutamate concentrations have been 
documented in liver and bile[1] and can serve as sub-
strate pools for glutamate transporters predominantly 
expressed at the canalicular side of  the hepatic cell[2]. 
Amongst the glutamate transporters (EAATs 1-5) de-
scribed so far[3], GLT-1/EAAT2 has been well-docu-
mented in the liver[4-6]. However, its role is not yet fully 
understood, although many reports have demonstrated 
that glutamate transporters are subject to direct regula-
tion at the transcriptional, translational and posttransla-
tional levels[7]. Glutamate transporters directly or indi-
rectly cross-talk with proteins inserted within the same 
membrane or with several intracellular signaling path-
ways[8-11]. Protein kinase C (PKC) represents one of  the 
widely studied intracellular pathways that control both 
the activity and the expression of  glutamate transporters. 
Such a functional relationship has been demonstrated in 
several models, particularly of  central nervous system 
origin[9,12-14]. Activation of  PKC in the liver is correlated 
with the appearance of  symptoms related to cholestasis. 
Indeed, a clear positive and negative modulation of  bile 
flow has been reported in the rat liver following PKC 
activation. Such an effect was correlated with the regula-
tion of  both apical exocytosis and sinusoidal bile acid 
uptake[15]. In vitro, down-regulation of  MRP2 transporter 
expression, a potential condition related to cholestasis 
development, has been demonstrated in human HepG2 
cells treated with PKC activator[16]. Together, these data 
support the investigation of  the potential involvement 
of  glutamate transporters in liver physiopathology.
In the current study, we demonstrate that PMA me-
diated activation of  PKC in HepG2 cells, an experimen-
tal condition mimicking liver cholestasis, and modulated 
both EAAT2 transporter activity and expression. In vivo, 
EAAT2 expression in the livers of  bile duct ligated rats 
and in human specimens of  cholestatic disease was up-
regulated. These alterations in GLT-1/EAAT2 expres-
sion observed in both experimental in vitro and in vivo 
models of  cholestasis suggest involvement of  the gluta-
mate system as part of  the liver response or as a direct 
liver target of  cholestasis.
MATERIALS AND METHODS
Materials
PMA, 4’,6-diamidino-2-phenylindole (DAPI), L-aspartate 
and phenylarsine oxide (PAO) were obtained from Sigma, 
Ro-8220 and PD98056 were from Calbiochem, and 
D-[3H]-aspartate was from Amersham (Amersham Phar-
macia Biotech, Roosendaal, Netherlands). Anti-GLT-1/
EAAT2 antibody was purchased from Abcam (Cambridge, 
United Kingdom), and anti-actin and anti-MRP2 anti-
bodies were provided by Sigma and Alexis Biochemicals, 
respectively. L-trans-pyrrolidine-2,4-dicarboxylic acid (t-
PDC) and threo-beta-benzyloxyaspartate (TBOA) were 
purchased from Tocris (Bristol, United Kingdom) and 
dihydrokainic acid (DHK) was from Ocean Product 
International (Nova Scotia, Canada). The culture me-
dium, penicillin, streptomycin, non-essential amino acids, 
pyruvate sodium, trypsin-EDTA, reverse transcription 
(RT) kit, elongase and PCR primers were obtained from 
Invitrogen (Merelbeke, Belgium). Fœtal calf  serum was 
purchased from Perbio Science (Erembodegem, Belgium).
Cell culture
HepG2 cells were cultured in plastic flasks (CELLSTAR®, 
Greiner Bio One) using DMEM containing 4.5 g/L glu-
cose (Ref  number: 41965-039) medium supplemented 
with 10% fetal calf  serum, 1% non-essential amino 
acids, 1% pyruvate sodium, and 1% penicillin-strepto-
mycin. At confluence, cells were routinely lifted using 
0.05% trypsin-EDTA and replated at a 1:10 dilution. All 
cultures were maintained at 37 ℃ in a water-saturated 
atmosphere containing 5% CO2. All culture media and 
consumables were from Invitrogen.
Animals and bile duct ligation
Experiments performed in this study were approved 
by the local ethical review board. Male Wistar rats were 
subjected to a 12-h day-night rhythm with free access to 
food and water. Four sham and 4 bile duct ligated rats 
were used for these experiments. Animals were anesthe-
tized with an intraperitoneal injection of  xylazine/ket-
amine, and were randomly assigned to bile duct ligation 
or sham operation. Briefly, the common bile duct was 
identified, double-ligated close to the liver hilus and cut 
between the ligatures. In sham-operated rats, the bile 
duct was only identified and exposed. Fifteen days later, 
livers were harvested for analysis. Specimens were fixed 
in formalin for 48 h and embedded in paraffin.
Human liver samples
Cholestatic human liver tissue was obtained from the 
resected livers of  patients undergoing orthotopic liver 
transplantation for biliary cirrhosis, due to biliary atresia 
(BA) (n = 4) or progressive familial intrahepatic cholesta-
sis (PFIC) (n = 4). For controls, we used 3 liver speci-
mens from patients transplanted for a non-cholestatic 
liver disease (2 Crigler Najjar and 1 oxalosis). Use of  
these tissues for research purposes was approved by the 
institution review board and the patient’s representative 
gave approval. Samples of  liver tissue were fixed in for-
malin for 24-48 h and embedded in paraffin.
Uptake activity
At 80% confluence, plates with hepG2 cells were placed 
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at the surface of  a 37 ℃ water bath, rinsed twice with 
preheated Krebs buffer[8] and then treated with drugs 
or vehicles. For the saturation studies, D-[3H]-aspartate 
(30 nmol/L) was diluted with unlabeled L-aspartate to 
achieve final aspartate concentrations of  1-200 μmol/L. 
Inhibitors were added 15 min before the addition of  
PMA. Unless stated, uptake was stopped after 6 min by 
3 rinses with ice-cold Na+-free Krebs buffer in which 
NaCl was substituted with equi-osmolar choline chloride. 
The cells were lysed with 500 μL of  1 N NaOH and the 
radioactivity of  200 μL of  the lysate was determined by 
liquid scintillation counting. A fraction of  the lysate was 
also used for protein determination. The specific activity 
of  the glutamate transporters (expressed as the uptake 
velocity per mg of  protein) was estimated after subtract-
ing the data obtained using Na+-free Krebs buffer. 
Reverse transcription-polymerase chain reaction assay 
Total RNA was extracted from cells grown in 6 well-
plates using the TriPure isolation reagent and cDNA was 
generated using the reverse transcription kit, according 
to the manufacturer’s instructions. Polymerase chain 
reaction (PCR) amplifications targeting EAAT2 and 
GAPDH were performed using polymerase elongase in 
a final volume of  25 μL and appropriate primers (EAAT2 
sense: 5’-aaatgaatggtgttgtcctgg-3’, EAAT2 antisense: 5’
-cttcatgtcatcataaatgg-3’ and GAPDH sense: 5’-cggagt-
caacggatttggtcgtat-3’, GAPDH antisense 5’-agccttctccat-
ggtggtgaagac-3’) generating distinct amplification prod-
ucts (341 and 307 base pairs for EAAT2 and GAPDH, 
respectively). After 26, 28 and 30 cycles of  amplification 
consisting of  denaturing at 94 ℃ for 30 s, annealing at 
60 ℃ for 60 s and extension at 72 ℃ for 90 s, samples 
were electrophoresed on a 1% agarose gel and nucleic 
acids were visualized by ethidium bromide staining.
Immunoblot analysis
Total extract samples were mixed with loading buffer 
(125 mmol/L Tris HCl, 50 mmol/L dithiothreitol, 4% 
sodium dodecyl sulfate, 20% glycerol, 0.01% bromo-
phenol blue, pH 6.8), boiled for 5 min and loaded onto 
5% sodium dodecyl sulfate-polyacrylamide gel accord-
ing to Laemmli[17]. After electrophoresis, proteins were 
transferred to nitrocellulose membranes with a Bio-Rad 
minitransblot electrophoretic transfer cell. Non-specific 
immunodetection was prevented by incubating the nitro-
cellulose membranes in TBS buffer (50 mmol/L Tris pH 
8.1, 150 mmol/L NaCl) containing 10% dry milk and 
0.05% Tween-20 for 1 h with gentle shaking at room 
temperature. The membranes were thereafter probed 
with affinity-purified mouse anti-MRP2 (Alexis Bio-
chemicals, 0.5 μg/mL) or rabbit anti-actin (Sigma, 1:1000) 
diluted in blocking solution for 18 h at 4 ℃. The anti-
gen-antibody complex was visualized with a horseradish 
peroxidase-conjugated anti-mouse (Amersham, 1:6000) 
or goat anti-rabbit IgG secondary antibody (Sigma, 
1:3000). Immunoreactive proteins were detected using 
enhanced chemiluminescence reagents (Perkin-Elmer).
Evaluation of cell damage
Cell viability following PMA treatment was evaluated by 
analyzing HepG2 cell culture supernatants for lactate de-
hydrogenase (LDH) (Cytotoxicity detection kit, Roche). 
Intracellular ATP concentrations were also semi-quantita-
tively measured in HepG2 cell cultures using a commer-
cially available kit (ATP Bioluminescence Assay Kit CLS 
Ⅱ, Roche) according to the manufacturer’s instructions.
Immunofluorescence confocal microscopy
HepG2 cells were plated on sterile glass coverslips and 
treated for 4 h with 500 nmol/L PMA or vehicle. Cells 
were then washed twice in PBS and fixed in 4% parafor-
maldehyde for 20 min at room temperature. After wash-
ing, cells were permeabilized with 0.1% Triton X-100 for 
15 min and blocked with 5% dry milk in TBS for 1 h at 
room temperature. The cells were incubated with anti-
EAAT2 primary antibody (1:50) in the blocking solution 
for 1 h at room temperature. After three washes with 
TBS, cells were further incubated with a fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-rabbit antibody 
for 1 h at room temperature (1:500, Sigma, Bornem, Bel-
gium). Cells were washed with TBS solution three times, 
once with PBS and the coverslips were mounted on glass 
slides in Mowiol with 2.5% DABCO overnight at room 
temperature and examined with an Axiovert confocal 
microscope (Zeiss, Oberkochen, Germany) coupled 
to MRC 1024 confocal scanning equipment (Bio-Rad, 
Richmond, CA, United States).
Immunohistochemistry 
Immunohistochemistry of  both animal and human liver 
samples was performed on 5 μm-thick liver sections that 
were deparaffinized and rehydrated in a graded alcohol 
series. After endogenous peroxidase activity blockade 
by incubation for 15 min in a 3% hydrogen peroxide 
methanol solution, the slices were incubated with citric 
acid monohydrate solution (pH 6.0) at 97 ℃ for 90 min 
for antigen retrieval. Non-specific immuno-staining was 
prevented by incubation in PBS buffer containing 1% 
normal goat serum for 1 h at room temperature. Slices 
were thereafter incubated overnight with polyclonal anti-
EAAT2 antibody at a dilution of  1/4000 at room tem-
perature.
Staining was visualized by EnVision + System-HRP 
Labeled Polymer Anti-Rabbit (DAKO) using diamino-
benzidine (Sigma, Belgium) as a chromogenic substrate. 
The nuclei were counterstained using Mayer’s hema-
toxylin for 10 min. Preparations were then mounted for 
microscopic analysis.
Statistical analysis
Data from the glutamate uptake experiments were ana-
lyzed by nonlinear regression using the curve-fitting 
program (GraphPad Software, San Diego, CA, United 
States). Statistical analysis of  the data was performed 
using GraphPad Prism software. Statistical differences 
were determined by the Student’s t test for two-group 
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comparison or by One-way ANOVA followed by the 
Tukey’s test for multiple comparisons between more 
than two groups. A probability of  P < 0.05 was consid-
ered significant.
RESULTS
Expression of GLT-1/EAAT2 transporter in HepG2 cells
As explained in the Methods section, glutamate trans-
port was evaluated in HepG2 cells following incuba-
tion with radiolabeled D-aspartate, a non-metabolizable 
analog of  glutamate, for 6 min. Significant specific Na+-
dependent D-[3H]-aspartate uptake was measured and 
no uptake was detected using Na+-free buffer (data not 
shown). When HepG2 cells were incubated with the 
non-selective transportable inhibitor, t-PDC, or the non-
transportable inhibitor, TBOA, Na+-dependent aspartate 
uptake was completely abolished (Figure 1A) indicating 
the involvement of  high affinity glutamate transport-
ers. The use of  DHK, a selective inhibitor of  EAAT2 
mediated uptake, demonstrated that EAAT2 was the 
predominant glutamate transporter expressed in HepG2 
cells (Figure 1A).
Further glutamate transport characterization was 
performed after incubating HepG2 cells with increasing 
concentrations of  the substrate. Non-linear analysis of  
D-[3H]-aspartate uptake revealed a maximal velocity of  
0.220 ± 0.001 nmol/mg of  protein/min and a Km value 
of  17.1 ± 2.6 μmol/L (Figure 1B). RT-PCR analyses (data 
not shown) and immunofluorescence confirmed the ex-
pression of  EAAT2 transporter in HepG2 cells (Figure 
1C). Together these data demonstrate that HepG2 cells 
primarily express functional EAAT2 glutamate trans-
porters.
Effect of acute PMA treatment on D-[3H]-aspartate 
uptake activity in HepG2 cells
We thereafter examined if  EAAT2 transporter activ-
ity could be regulated after PKC activation. To do so, 
HepG2 cells were exposed to 500 nmol/L PMA for 15 
min and aspartate uptake was evaluated for 6 min. Non-
linear analysis of  the specific uptake of  D-[3H]-aspar-
tate/L-aspartate isotopic dilutions revealed that PMA 
treatment decreased EAAT2-mediated uptake capacity 
by 60% (Bmax values of  0.220 ± 0.001 nmol/mg of  pro-
tein/min for control cells and 0.088 ± 0.005 nmol/mg of  
protein/min for PMA-treated cells) as well as EAAT2 af-
finity for the substrate (Km values of  17.1 ± 2.6 μmol/L 
for control and 27.1 ± 4.3 μmol/L for PMA-treated cells) 
(Figure 2A). The effect of  PMA on aspartate uptake was 
concentration-dependent as shown in Figure 2B and was 
maintained after prolonged exposure (Figure 2C). A 90% 
decrease in aspartate uptake capacity was reached when 
HepG2 cells were incubated for 60 min with PMA. This 
decrease in aspartate uptake was not associated with a de-
crease in cell viability as no difference in ATP levels was 
observed between PMA and vehicle-treated cells (Figure 
2C, inset). Involvement of  the PKC pathway in modu-
lating EAAT2-mediated glutamate uptake in HepG2 
cells was confirmed by the complete abolition of  the 
observed effect using the PKC inhibitor Ro-31-8220 (1 
μmol/L) (Figure 3A). Besides PKC activation, PMA also 
indirectly modulated other closely connected pathways. 
To investigate the involvement of  additional mediators in 
such modulation, HepG2 cells were pretreated with the 
MEK inhibitor, PD98059 (10 μmol/L). No inhibition of  
the PMA-mediated decrease in aspartate uptake was ob-
served (Figure 3A).
As the inhibition of  aspartate uptake observed in 
HepG2 cells after PMA treatment could be correlated 
with internalization of  transporter molecules from the 
plasma membrane, cells were pretreated with PAO in 
order to block both internalization and membrane inser-
tion processes[18-20]. In PAO pre-treated cells, a partial 
inhibition of  the PMA effect was observed (Figure 3B) 
suggesting that internalization of  glutamate transporters 
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Figure 1  Characterization of Na+-dependent D-[3H]-aspartate uptake in HepG2 hepatoblastoma cells. A: D-[3H]-aspartate (30 nmol/L) uptake was measured 
after 6 min incubation with intact HepG2 cells treated with vehicle (controls), t-PDC (1 mmol/L), TBOA (1 mmol/L) or DHK (100 μmol/L) for 15 min. Data shown are 
mean ± SE of at least three independent experiments performed in quadruplicate. bP < 0.001 as compared to control (paired student t-test); B: Saturation isotherms 
for D-[3H]-aspartate (1-100 μmol/L) uptake measured in HepG2 cells. Data shown correspond to mean values with SE from quadruplicate measures on four indepen-
dent series; C: Immunofluorescence detection of EAAT2 transporter on HepG2 cells using specific polyclonal antibody. Immunoreactivity was visualized using a FITC-
conjugated rabbit anti-goat antibody, and cell nuclei appear in blue (DNA staining with DAPI) (original magnification × 200). t-PDC: L-trans-pyrrolidine-2,4-dicarboxylic 
acid; TBOA: Threo-beta-benzyloxyaspartate; DHK: Dihydrokainic acid; DAPI: 4’,6-diamidino-2-phenylindole.
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is part of  the mechanism (in addition to decreased affin-
ity) behind the decrease in HepG2 cells’ ability to take 
up aspartate. Together these data suggest the potential 
of  PKC to modulate both EAAT2-mediated transport 
activity and membrane localization.
Effect of long-term PMA treatment on D-[3H]-aspartate 
uptake activity and expression in HepG2 cells
We then focused on the behavior of  the EAAT2 trans-
porter after long-term PKC activation. These experimen-
tal conditions have been shown to mimic liver cholesta-
sis by inducing down-regulation of  MRP2 transporter 
expression from apical membranes in these cells and in 
perfused rat liver[15]. In our study, we first confirmed the 
dramatic loss of  MRP2 canalicular immunoreactivity in 4 
h PMA-treated HepG2 cells using immunofluorescence 
(Figure 4A). We further investigated EAAT2 glutamate 
transporter activity after 1, 2 and 4 h by evaluating uptake 
after incubation with radiolabeled aspartate for 6 min. As 
shown in Figure 4B, a 90% decrease in aspartate uptake 
was observed in PMA-treated HepG2 cells as compared 
to controls, an effect that was observed after 1 h and was 
unchanged up to 4 h. The decreased uptake activity was 
not correlated with altered cell viability as demonstrated 
using the LDH assay at the longest period of  PMA treat-
ment (Figure 4B inset). This suggests that chronic PKC 
activation maintained decreased EAAT2 activity.
Confocal microscopy was used to evaluate whether 
decreased aspartate uptake observed after PMA treat-
ment was correlated with internalization of  EAAT2 
membranous transporters. After immunostaining, la-
beled cells were scanned under 488 nm wavelength ex-
citation and images were acquired as single transcellular 
optical sections. As shown in Figure 4C, under control 
conditions, EAAT2 immunoreactivity appeared predom-
inantly at the cell surface with concomitant intracellular 
staining (Figure 4C). After PMA treatment, immuno-
reactivity was concentrated in the peri-nuclear region, 
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Figure 2  Modulation of aspartate uptake capacity by phorbol 12-myristate 13-acetate in HepG2 cells. A: Saturation curve for D-[3H]-aspartate uptake measured 
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plus Ro-31-8220 not significantly different). PD09859, a selective inhibitor of the 
MAPK pathway, failed to prevent the PMA-decrease in aspartate uptake; B: Ef-
fect of L-aspartate and phenylarsine oxide (PAO) on basal and PMA-decreased 
aspartate uptake in HepG2 cells. Cells were pretreated with PAO (10 μmol/L) or 
vehicle for 15 min. Thereafter, PMA (500 nmol/L) was added and the uptake as-
say was performed after 15 min. Results are expressed as percent of untreated 
cells and correspond to means ± SE of at least three independent experiments 
performed in triplicate. Statistical analysis was performed by One-way ANOVA 
followed by the Tukey’s test for multiple comparisons. aP < 0.05; bP < 0.001 vs 
the corresponding untreated control cells; and dP < 0.001 denotes a difference 
between PMA-treated cells with or without the pharmacological agent.
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whereas very low immunostaining was observed at the 
membrane. EAAT2 transporter molecules were par-
ticularly redistributed into large vesicular compartments 
within the cell suggesting a possible transfer into late en-
dosomal or lysosomal pathways. These data suggest that 
internalization of  EAAT2 cell surface transporters is 
involved in the inhibition of  aspartate uptake observed 
after chronic PKC activation. We further examined if  
EAAT2 genetic expression was affected. Using RT-PCR, 
analysis of  EAAT2 transporter mRNA level revealed 
that PMA stimulated the expression of  this transporter 
as compared to control cells (Figure 5A). The effect of  
PMA was observed after 26 and 28 cycles of  amplifica-
tion and was specific to the EAAT2 transporter as the 
amplification of  GAPDH cDNA appeared similar in the 
controls and PMA-treated cells (Figure 5B).
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EAAT2/DAPI MRP2/DAPI EAAT2/MRP2/DAPIA
Figure 4  Effect of long-term treatment with phorbol 12-myristate 13-acetate on EAAT2 expression in HepG2 cells. A: Effect of phorbol 12-myristate 13-ac-
etate (PMA) on multidrug resistance protein 2 (MRP2) cell surface distribution. Cells were treated with 500 nmol/L PMA (lower panels) or vehicle (upper panels) for 4 
h, fixed and incubated with anti-EAAT2 and anti-MRP2 primary antibody. Immunoreactivity was visualized using FITC-conjugated rabbit anti-goat and cyanine-3-
conjugated goat anti-mouse antibodies respectively. Cell nuclei appear in blue (DNA staining with DAPI). In control HepG2 cells, the MRP2 transporter is mainly local-
ized at the canalicular side. Such organization is absent in PMA-treated cells. Images were representative of several fields examined from 3 independent experiments 
(original magnification × 200); B: Effect of pre-treating HepG2 cells with PMA for 1, 2 and 4 h on D-[3H]-aspartate uptake. Data are expressed as percent of control 
and correspond to mean ± SE of three independent experiments performed in sextuplicate. Inset shows the data obtained after the analysis of extracellular LDH lev-
els in HepG2 cell cultures treated with 500 nmol/L PMA or vehicle for 4 h. Data shown correspond to mean values ± SE of typical experiments performed four times; 
C: Effect of PMA treatment on EAAT2 immunostaining distribution in HepG2 cells was analyzed by confocal microscopy. Cells were treated with 500 nmol/L PMA or 
vehicle for 4 h, fixed and incubated with anti-EAAT2 primary antibody. Immunoreactivity was visualized using a fluorescein isothiocyanate-conjugated goat anti-rabbit 
antibody. Images (single optical slides through the cells) were representative of several fields examined from 3 independent experiments. Original magnification is × 
200 for controls and × 400 for PMA treated groups. Scale bar, 20 μm. DAPI: 4’,6-diamidino-2-phenylindole; LDH: Lactate dehydrogenase.
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Expression of GLT-1/EAAT2 transporter in the liver of 
bile duct-ligated rats and human cholestatic disease
Based on the data obtained in HepG2 cells, it may be 
surmised that in vivo GLT-1/EAAT2 transporter expres-
sion is modulated in liver cholestasis. Therefore, GLT-1 
immunoreactivity was analyzed in rat liver 15 d after 
bile duct ligation (BDL). Using immunoblotting, we 
first evaluated the effect of  this surgical intervention on 
the expression of  MRP2 transporter. As shown in Fig-
ure 6A, a marked loss in MRP2 protein expression was 
observed after BDL, whereas no changes were seen in 
actin expression, used as the internal control, between 
the sham-operated and BDL rats. We then analyzed the 
expression of  GLT-1 transporter in paraffin-embedded 
liver sections using immunohistochemistry. At the anti-
GLT-1 antibody concentration used, no staining was 
observed in sham-operated rats (Figures 6B1 and 6B3), 
whereas strong up-regulation of  cell surface GLT-1 
transporter expression was observed in all the mem-
branes of  hepatocytes in BDL rats (Figures 6B2 and 
6B4). These results, although contrary to the results ob-
tained in the HepG2 cell line, confirm that the expres-
sion of  EAAT2/GLT-1 transporter is altered during in 
vivo cholestasis.
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Figure 5  Effect of phorbol 12-myristate 13-acetate treatment on EAAT2 mRNA expression in HepG2 cells. Reverse transcription polymerase chain reaction 
(PCR) analysis of phorbol 12-myristate 13-acetate (PMA)-treated HepG2 cells for EAAT2 (A) and GAPDH (B) mRNA levels. Total mRNA was isolated from HepG2 
cells treated with vehicle (C) or 500 nmol/L PMA for 4 h (P) as described in Methods. EAAT2 (341 base pairs) and GAPDH (302 base pairs) mRNAs were amplified by 
26, 28 and 30 PCR cycles in the presence of specific primers and separated on a 1.5% agarose gel stained with ethidium bromide. M: Molecular marker.
MRP2
Actin
Control BDL
BA Sham Rat BDL
Figure 6  GLT-1/EAAT2 transporter expression in rat liver after bile duct ligation. A: Immunoblot analysis of multidrug resistance protein 2 transporter and actin 
protein expression in the liver of sham-operated (control, n = 4) and bile duct ligated (BDL, n = 4) rats. Fifty µg of total protein extract were loaded and subjected 
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Immunoblots are representative of at least three independent experiments; B: Immunohistochemical 
localization of the GLT-1/EAAT2 transporter in liver sections of sham operated (B1, B3) and bile duct ligated (B2, B4) rats. Immunohistochemistry was performed on 
paraffin-embedded liver sections using specific antibody for GLT-1 as described in Methods. (B1 and B3) in sham-operated liver rats, no GLT-1 immunoreactivity is 
observed in hepatocytes. After BDL, (B2 and B4) GLT-1 immunoreactivity is detected as a specific cell surface staining in hepatocytes [original magnification × 200 (B1, 
B2) and × 400 (B3, B4) respectively].
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Analysis of  human liver disease specimens revealed 
that control non-cholestatic liver specimens showed rare 
focal cell surface immunostaining of  hepatocytes with-
out any specific topography in the liver lobule (Figure 
7A). In cholestatic liver slices, plasma membrane expres-
sion of  EAAT2 transporter, as in BDL rats, increased 
in all membranes of  the diseased hepatocytes. In geneti-
cally proven progressive familial intrahepatic cholestasis 
type 2 (PFIC 2) samples, the immunostaining remained 
focal (Figure 7B), whereas in BA (Figure 7C) and PFIC 
3 (Figure 7D) strong membranous labeling was present 
in numerous hepatocytes. In PFIC 3, this labeling was 
concentrated in the periportal tract. 
DISCUSSION
Using PMA-treated human hepatoblastoma HepG2 
cells, the current study demonstrated that EAAT2 gluta-
mate transporter expression and activity were modulated 
under experimental cholestasis conditions. In vivo, we 
showed an up-regulation of  EAAT2/GLT-1 glutamate 
transporter protein expression in the membranes of  he-
patocytes of  both bile duct-ligated rats and cholestatic 
human liver samples in which high levels of  GGT were 
noted. Although divergent, the in vitro and in vivo data 
from the current study confirm the involvement of  glu-
tamate transport systems in liver physiopathology.
Liver is a major site of  glutamate synthesis and dis-
plays all the related enzymatic pathways. Hepatic tissue 
concentrations of  glutamate are approximately 30 times 
higher than plasmatic concentrations[2,21,22] suggesting 
that sinusoidal glutamate uptake activity is low. High 
glutamate concentrations are also found in bile and do 
not originate from direct secretion of  free glutamate. 
These high levels are generated within the biliary tree by 
the action of  GGT on glutathione secreted into bile[2]. 
The glutamate transport system detected in the canalicu-
lar membrane may then serve to reclaim some of  this 
amino acid. 
According to its important intermediary metabolic 
role in liver ammonia detoxification, gluconeogenesis 
and acid-base balance, the control of  hepatic glutamate 
transport may significantly modulate its availability and 
these related intrahepatic metabolic processes. Indeed, 
glutamate transport across the liver sinusoidal membrane 
is currently documented to be important for controlling 
liver nitrogen flux by modulating perivenous glutamine 
synthesis[23]. The activity of  glutamate transporters in 
liver sinusoidal membranes is influenced by a variety of  
factors in vivo including those which alter plasma amino 
acid composition or the Na+ electrochemical gradient. 
Modulation of  both the degree and the distribution of  
glutamate transporter expression within the liver may 
enhance the range of  hepatic response to a variety of  
physiological and physio-pathological challenges. This is 
the case for managing whole-body nitrogen metabolism, 
as demonstrated after starvation, diabetes and glucocor-
ticoids treatment[24].
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Figure 7  EAAT2 transporter expression in human cholestatic liver tissue. A: In non cholestatic liver disease, some rare hepatocytes show membranous staining; B: 
In PFIC type 2, this expression increased, but was still limited to some hepatocytes. In the case of biliary atresia (C) and progressive familial intrahepatic cholestasis 
(PFIC) type 3 (D), the membrane expression is strong and observed in numerous hepatocytes (original magnification × 200). 
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Several studies have reported the involvement of  
PKC in the regulation of  glutamate transport, especially 
in cell models of  central nervous system origin[9]. In the 
liver, activation of  this kinase leads to the induction of  
hepatic cholestasis as demonstrated in HepG2 cells and 
perfused rat liver[15,16]. Our results show that HepG2 cells 
specifically take up radiolabeled D-aspartate in a sodium-
dependent manner. To our knowledge, this is the first re-
port of  the presence of  functional glutamate transport-
ers in this human cell line, although other studies have 
demonstrated the presence of  such systems in rat hepa-
toma cells[25,26]. After demonstrating the predominance 
of  EAAT2 expression in this cell line, we showed that 
acute activation of  PKC decreased both EAAT2 affinity 
for the substrate and maximal transport velocity. These 
data were in part correlated with rapid internalization 
of  EAAT2 cell surface transporter molecules from all 
membranes. In previous studies, the decrease in GLT-1/
EAAT2 activity documented after PKC activation has 
been associated only with an internalization process[14] or 
with a decrease in the affinity for the substrate as dem-
onstrated in Y-79 human retinoblastoma cells[13]. In our 
study, the modulation of  the above uptake parameters 
of  the EAAT2 transporter may be related to the PKC 
subtype or to the GLT-1 isoform eventually expressed in 
HepG2 cells.
We subsequently revealed that long-term PKC acti-
vation maintained a marked decrease in EAAT2 trans-
porter activity and expression with no loss in cell viabil-
ity. Such experimental conditions have been shown to 
induce cellular symptoms of  cholestasis (down-regulation 
of  MRP2 transporter expression as confirmed by our 
group in PMA-treated HepG2 cells). Decreased EAAT2 
expression due mainly to an internalization of  cell sur-
face transporter molecules towards the intracellular 
compartment was demonstrated using confocal micros-
copy. Further studies are needed to determine if  these 
transporter molecules will be targeted for degradation 
or recycling in the plasma membrane. We were unable to 
study the immunoreactivity of  the EAAT2 transporter at 
the cell membrane and intracellular fractions as no spe-
cific signal was detected in western blotting experiments 
using the commercially available anti-EAAT2 antibody. 
By analyzing EAAT2 mRNA expression using RT-
PCR, we demonstrated that chronic activation of  PKC 
increased EAAT2 mRNA levels suggesting that this sig-
naling pathway is involved in the stimulation of  EAAT2 
gene transcription or the decrease in its mRNA destabili-
zation. This stipulates that cis-acting responsive elements 
for this kinase may be present in the 5’ or 3’ untranslated 
EAAT2 gene regions and that the PKC pathway may in-
directly control the long-term level of  the availability of  
extracellular glutamate in the liver. Furthermore, EAAT2 
mRNA up-regulation may suggest that EAAT2 mol-
ecules internalized after chronic activation are targeted 
to degradation.
We determined whether EAAT2 modulated expres-
sion was observed in vivo. Thus, EAAT2 protein expres-
sion was analyzed in the livers of  rats following BDL for 
2 wk. Using immunohistochemistry, our data revealed a 
marked up-regulation in hepatic GLT-1/EAAT2 expres-
sion after BDL, an experimental condition of  extrahe-
patic obstructive cholestasis. The discrepancy in the data 
obtained in vivo and in vitro may be related to the model 
of  cholestasis, which is of  intrahepatic origin in HepG2 
cells and extrahepatic in bile duct ligated rats. The pre-
dominant cell surface expression of  GLT-1 observed 
in hepatocytes after BDL revealed that transporters are 
oriented at all membranes of  hepatocytes to take up ex-
tracellular glutamate.
Using transport measurements, it was proposed that 
sodium gradient-dependent glutamate transport was 
localized only in the canalicular domain[2]. In our experi-
mental conditions, no immunostaining for GLT-1 was 
observed in control rat livers at the canalicular or the si-
nusoidal side. Nevertheless, it was clear that BDL stimu-
lated the cell surface expression of  this transporter in 
all hepatocyte membranes. This suggests a need for this 
amino acid, due to the low energetic pool that can occur 
after BDL. In addition, the high extracellular concentra-
tions of  glutamate at the plasmatic and biliary levels, 
as previously demonstrated in patients with high levels 
of  GGT[27], force the hepatocytes to reclaim this amino 
acid. No intracellular staining was observed in hepato-
cytes indicating that these cells are not able to synthesize 
new transporter molecules.
The presence of  free radicals, oxidative stress, and 
lipid peroxidation have been confirmed during cholesta-
sis[28-32]. This was attributed to the pro-oxidant potential 
of  hydrophobic bile acids highly accumulated inside the 
hepatocytes[33] and a consequent strong inflammatory 
response[34]. The up-regulation of  glutamate transport via 
the EAAT2/GLT-1 subtype could also be indirectly as-
sociated with liver glutathione synthesis, which is altered 
after cholestasis[35].
The antioxidant defence will activate the maintenance 
of  normal intracellular levels of  glutathione. Its de novo 
synthesis is closely related to an adequate supply of  pre-
cursor amino acids such as glutamate which may be sup-
plied via transporter activity[36]. Indeed, the free glutamate 
found in excreted bile is formed from the intra-biliary 
hydrolysis of  GSH due to the hydrolytic reaction of  
GGT[37]. Glutamate formed in the canalicular bile may be 
transported back into the liver via the identified canalicu-
lar glutamate transport systems[2]. The significance of  this 
is still unknown, although substantial intra-hepatic cycling 
of  specific biliary constituents was proposed. This com-
plex interacting pathway (GSH-GGT-Glutamate) may be 
altered in HepG2 cells according to the potential diver-
gent role of  GGT such as in tumour progression[36].
EAAT2 transporters are able to take up cysteine, one 
of  the three amino acid precursors of  glutathione, and 
synthesis can also be reduced if  glutamate transport is 
inhibited[38]. In this way, the demonstrated increase in 
EAAT2/GLT-1 transporter activity may help hepato-
cytes to avoid liver oxidative damage.
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A relationship between PKC and GSH has also been 
documented[39]. Indeed, negative regulation of  PKC has 
been reported consequent to GSH depletion as in oxida-
tive stress. Such depletion has been reported to remove 
the negative modulation of  PKC and to provide a per-
missive environment for its activity[40]. A decrease in liver 
GSH, induced by L-buthionine sulfoximine or diethyl-
maleate treatment, is accompanied by the inactivation 
of  classic PKC isoforms and increased activity of  novel 
PKC isoforms, in particular PKC-δ[41].
The cell surface expression of  EAAT2 transporter 
was confirmed in cholestatic human liver samples espe-
cially in BA and PFIC 3 patients, characterized by high 
levels of  GGT, as compared to non-cholestatic patients 
or PFIC 2. Hepatocytes are the principal bile produc-
ing liver cells (a complex fluid containing salts and 
phospholipids). Bile is delivered to the intestine via the 
bile ducts and acts like a detergent in order to dissolve 
fat and aid the absorption of  vitamins. An alteration in 
PFIC gene expression causes poor bile flow including 
salts (in PFIC-1 deficiency) or phospholipids (PFIC-3 
deficiency). The consequent accumulation of  such bile 
substances in the liver leads to hepatic damage and cho-
lestasis. In PFIC3 (MDR3 deficiency), GGT is present 
in large quantities in the canalicular and bile-duct mem-
branes. When these are damaged, GGT is released into 
the bile. GGT then leaks across the wall of  the biliary 
tract into the blood and the concentrations of  GGT in 
serum are augmented. GGT is lacking in the canalicular 
membranes in PFIC-1 patients. In PFIC-2, bile acids are 
not normally pumped into bile, although GGT is present 
in the canalicular membranes. Without the detergent ac-
tion of  bile acids, GGT cannot be released. The involve-
ment of  this enzyme in modulating membrane transport 
has already been demonstrated in vitro. Indeed, in GGT-
implanted human erythrocytes[42], an increase in amino 
acid translocation across cell membranes has been pro-
posed to be the result of  an increase in the transporter 
cell surface expression. The results of  this study support 
the potential role of  GGT as an intracellular pathway 
regulating glutamate transport through modulation of  its 
membrane localization of  transporters.
In summary, the current study demonstrates the in-
volvement of  the glutamate transport system in liver cho-
lestasis both in cellular and animal models as well as in 
humans. This may help in understanding the role of  glu-
tamate and acidic amino acid transport in liver diseases.
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L-glutamate, the most abundant intracellular amino acid in the liver, is involved 
in a wide variety of important hepatic metabolic pathways such as ureagenesis, 
gluconeogenesis and glutathione synthesis. Glutamate uptake is involved in 
controlling intracellular glutamate availability and is clearly implicated in dis-
eases of other organs such as the central nervous system. Although many of 
the metabolic pathways associated with glutamate are altered in several liver 
diseases, few studies on the role of glutamate uptake in liver physiopathology 
are available. 
Research frontiers
High glutamate concentrations are found both in the liver and bile as compared 
to plasma. Few data are available regarding the potential role of glutamate 
transporters in the liver, although this is well documented for other organs in-
cluding the brain. In the current study, the authors demonstrate the involvement 
of EAAT2-mediated glutamate transport in liver cholestasis. Altered hepato-
cytes, the major metabolic liver cells, modulate cell surface EAAT2 transporter 
molecule expression probably to normalize extracellular glutamate level and 
recover basal intracellular metabolic activities.
Innovations and breakthroughs
This is the first study to investigate the modulation of EAAT2 mediated gluta-
mate transport in human liver cholestasis.
Applications
Glutamate availability is very important for the execution of several intrahepatic 
pathways. Pharmacological modulation of its transport activity at the hepatic 
and/or extra-hepatic level should be taken into account as it may indirectly con-
trol/perturbate these hepatic metabolic pathways.
Peer review
The authors clearly demonstrated the alteration of glutamate handling by 
EAAT2 in cholestatic liver disease in humans both at the intrahepatic level as in 
progressive familial intrahepatic cholestasis and extrahepatic level as in biliary 
atresia. The study design is clear and the methodology used is appropriate and 
clearly described. Figures are clearly expressing the results in logical sequence 
that is in accordance with scientific thinking. The conclusion is strongly based 
on the obtained results from the experiments. 
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